Language
English
Publication Date
1-1-2025
DOI
10.1002/wnan.70004
PMID
39948059
PMCID
PMC11874078
PubMedCentral® Posted Date
1-1-2026
PubMedCentral® Full Text Version
Author MSS
Abstract
The clinical availability of photon-counting computed tomography (PCCT) has ushered in a new era of CT imaging. Spectral imaging coupled with superior contrast resolution, and ultrahigh spatial resolution (200 μm) offered by PCCT has the potential to revolutionize value-driven imaging. The potential of multicolor PCCT has generated excitement, and renewed interest, in novel contrast agent development for comprehensive disease interrogation, prediction and monitoring of treatment outcomes. Nanoparticles provide a versatile and powerful platform for the development of next generation contrast agents for spectral PCCT. In this article, we review recent developments and use of nanoparticle contrast agents for PCCT. We also discuss future research and translational opportunities for nanoparticle-based CT contrast agents enabled by the advent of PCCT and describe key considerations for their clinical translation.
Keywords
Contrast Media, Humans, Nanoparticles, Tomography, X-Ray Computed, Animals, Photons, cellular imaging, cellular tracking, computed tomography, molecular imaging, nanoparticle contrast agent, photon-counting CT, radiomics, spectral CT, theranostics
Published Open-Access
yes
Recommended Citation
Devkota, Laxman; Bhavane, Rohan; Badea, Cristian T; et al., "Nanoparticle Contrast Agents for Photon-Counting Computed Tomography: Recent Developments and Future Opportunities" (2025). Faculty, Staff and Students Publications. 6427.
https://digitalcommons.library.tmc.edu/baylor_docs/6427
Graphical Abstract